Mammogen Launches Dx Industry’s First E-Commerce Marketplace, Strengthening Its Leadership Position in Women’s Health


Mammogen – a woman-led precision diagnostics company – has launched a premier online marketplace designed to create a tangible bridge between science and the community

NEWPORT BEACH, Calif., September 13, 2022 /PRNewswire/ — mammogenica leading women’s health company specializing in non-invasive precision diagnostics, launched mammogenic market, an e-commerce platform designed to bring hope, comfort and support to those affected by women’s health-related illnesses. The company says it is the diagnostics industry’s first online marketplace to support the development of products and communities for patients and those who love them.

The Pink Robe Killer’s mission: To raise breast cancer awareness and replace uncomfortable pink paper mammography robes.

Mammogen was founded and is currently owned and operated by IV BioHoldings (IVBH), a leading bio-AI platform company in the growing liquid biopsy industry. “Being a patient-centric organization requires a willingness to integrate technology across all areas of the business,” said IVBH Founder and CEO Marty Keiser, who is also President of Mammogen. “The marketplace is an important step in proving that the community can drive market adoption. and that market adoption can, in turn, fuel the community.”

Elizabeth Cormier-May, CEO of Mammogen and Chief Commercial Officer of IVBH, designed the marketplace after hundreds of conversations with patients and families impacted by breast cancer. According to Cormier-May, the comfortable gear and accessories available on the mammogenic market are designed to raise awareness and provide solutions to key unmet women’s health needs, all through a centralized resource haven.

“Innovation shouldn’t be limited to our science and product development,” Cormier-May said. “We have tapped into the same level of creativity from which Mammogen was born to completely redefine traditional brand building, revenue generation and the development of non-clinical solutions that elevate and empower the patients and families we serve. this market to help build a bridge between science and the community is essential to ensuring that Mammogen remains at the forefront of an ever-changing healthcare landscape.”

“Today, we are focusing on important breast health issues and raising awareness of the important role non-invasive diagnostics play in improving patient experience and outcomes. Over time, our focus is to transform the mammogen market into an expansive platform that bridges the gap between science and community for all women, affected by all diseases, everywhere,” said Cormier-May.

Mammogen has partnered with Tee Commerce to create its marketplace. Tee Commerce, an e-commerce service provider that built a new business initially focused on the golf industry, jumped at the chance to back a company with a patient-centric vision. Founded by childhood cancer survivor Ben Vainer, Tee Commerce understands the importance of early disease detection and has partnered with Mammogen to bring the company’s unique vision to life.

“We were honored to power Mammogen’s entry into e-commerce,” said Collin Lynch, COO of Tee Commerce. “After understanding how mammogen’s market would evolve, we worked diligently to stock their store with health and comfort-focused products. We look forward to seeing Mammogen’s new healthcare model usher in a new era of patient-centered care.

The market’s flagship, The Pink Robe Killer – described by Cormier-May as a “plush, comfortable zipper” – is intended to replace the impersonal, cold pink paper dresses that most women wear on their date nights. mammography. Cormier-May hopes the product will serve to remind women to put their own health first, make personal care synonymous with comfort, and help the company continue to fuel innovation in women’s health. women.

For more information visit:

About Mammogen

Mammogen is a women-led precision health company dedicated to radically improving the detection, diagnosis and treatment of diseases related to women’s health, and building a diverse and thriving global community. that encourages, empowers and uplifts women along the survival, end-for-never-end journey. Mammogen’s flagship genTRU diagnostic program is a clinical-stage, patent-pending technology that measures changes in RNA expression patterns, found in blood and saliva, to provide highly accurate diagnosis. breast cancer consistently across all stages of the disease. The genTRU-breast diagnostic suite is intentionally designed to exclude good women from imaging and intervention much earlier and to exclude bad women from unnecessary procedures. It is positioned to unlock regular and reliable screening for millions of women around the world. Visit:

Quote Show original content to download multimedia:

SOURCE IV BioHoldings


Comments are closed.